A Phase 4 interventional study of Enzalutamide and Abiraterone in Prostate Cancer, sponsored by Pfizer. Completed at 95 sites in 11 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-18.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 16th largest by enrollment, is one of 8 that started in 2013, is one of 7 in phase 4, and was the 22nd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 509 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Prostatic Neoplasms by Pfizer: 3 open now, 8 under way, 5 of them phase 3. Of 33 finished, 28 (85%) have results posted.
Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the 11th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2013, is the only one in phase 4, and was the 18th registered.
Pfizer’s Prostatic Neoplasms studies by the year they started, since 1998.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Pfizer’s 42 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily
Drug: Enzalutamide · Drug: Abiraterone · Drug: Prednisone
Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.
Drug: Abiraterone · Drug: Placebo for Enzalutamide · Drug: Prednisone
160 mg by mouth once daily
Also known as: MDV3100, Xtandi
1000 mg by mouth once daily
Also known as: Abiraterone acetate, Zytiga
Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
5 mg by mouth twice daily
Also known as: prednisolone
Progression Free Survival (PFS)
PFS = time from randomization to first documentation of radiographic progression (RP),unequivocal clinical progression or death due to any cause (death within 112 days of treatment discontinuation without objective evidence of RP),whichever occurred first as per investigator. Unequivocal disease progression was pain requiring chronic administration of analgesics, decline of prostate cancer of Eastern Cooperative Oncology Group (ECOG) performance status score to 3 or higher or initiation of new anticancer therapy/radiation therapy or surgical intervention due to tumor progression. ECOG score range= 0(no severity) to 5(maximum severity).RP for bone disease was evaluated by appearance of 2 or more new bone lesions as per Prostate Cancer Clinical Trials Working Group 2 (PCWG2) or for soft tissue disease according to Response Evaluation Criteria in Solid Tumor version 1.1. Participants with no PFS event at analysis date were censored at last tumor assessment date prior to data cutoff date.
Time frame: From randomization until disease progression, last tumor assessment without disease progression or death due to any cause, whichever occurred first (maximum up to 20.3 months)
Time to Prostate Specific Antigen (PSA) Progression
Time from date of randomization to the date of first confirmed PSA progression as per Prostate Cancer Clinical Trials Working Group 2 (PCWG2). For participant's whose PSA decreased at Week 13 after randomization, progression was defined as 25 percent (%) PSA increase relative to nadir or absolute increase of \>=2 nanogram/milliliter (ng/mL) above nadir. Progression was confirmed if another assessment measured at least 3 weeks later met the criterion as well. For participant's whose PSA did not decrease at Week 13 after randomization, progression was defined as 25% PSA increase relative to baseline assessed 12 weeks after baseline. Participants who were not known to have had a PFS event at the analysis date were censored at last PSA assessment date prior to data cutoff date.
Time frame: From randomization until disease progression, last tumor assessment without disease progression, whichever occurred first (maximum up to 11.1 months)
Prostate Specific Antigen (PSA) Response Rate
PSA response rate was defined as percentage of participants with \>=30% and \>=50% decrease in PSA from baseline at randomization to the maximal PSA response with a threshold of 30% and 50% respectively. PSA response was confirmed if another assessment measured at least 3 weeks later met the criterion as well.
Time frame: From randomization until disease progression, last tumor assessment without disease progression, whichever occurred first (maximum up to 11.1 months)
Objective Response Rate (ORR)
Objective response rate as assessed by the investigator according to Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST v1.1) was defined as 1) Percentage of participants with confirmed best overall complete response (CR) and partial response (PR); 2) Percentage of participants with CR, PR and stable disease (SD) for target lesions or non-progressive disease for non-target lesions. CR: Disappearance of all non-nodal target and non-target lesions, including target and non-target lymph nodes reduction to \<10 millimeter (mm) in short axis. No new lesions and disappearance of all non-target lesions. PR: \>= 30% decrease in sum of diameters of target lesions, compared to the sum at baseline. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions.
Time frame: From randomization until CR or PR, whichever occurred first (maximum up to 21.3 months)
Rate of Pain Progression
Rate of pain progression was defined as percentage of participants with an increase of \>=30% from baseline in the mean Brief Pain Inventory-Short Form (BPI-SF) pain intensity item scores of 4 items assessing average, worst, least, and intermediate pain severity. BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. BPI-sf includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). BPI-sf score range for each item was from 0=no pain to 10=worst possible pain. Total score was reported as average of individual questions ranges from 0 to 10, where lower scores indicated less pain or less pain interference.
Time frame: Month 6
Time to First Use of New Antineoplastic Therapy for Prostate Cancer
It was defined as time from randomization to the date of first use of subsequent antineoplastic therapy for prostate cancer. For participants who had not started subsequent antineoplastic therapy as of data analysis cutoff date, the time to first use of subsequent antineoplastic therapy was censored at the date of last assessment.
Time frame: From randomization until date of first use of any antineoplastic therapy (after last dose date of Period 2, maximum up to 22.3 months
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 where higher scores represent better quality of life.
Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Social/Family Well-Being Domain Scores
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for social/family well-being domain is from 0 (worst response) to 32 (best response), where higher score indicate better quality of life.
Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Emotional Well-Being Domain Scores
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for emotional well-being domain is from 0 (worst response) to 24 (best response), where higher score indicate better quality of life.
Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Functional Well-Being Domain Scores
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for functional well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.
Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Prostate Cancer Domain Scores
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for prostate cancer domain is from 0 (worst response) to 48 (best response), where higher score indicated better quality of life with fewer symptoms.
Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Physical Well-Being Domain Scores
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for physical well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.
Time frame: Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89
Time to Degradation of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score
Time to degradation of FACT-P was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the global FACT-P score for each participant. The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, and functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 with higher scores representing better quality of life. Participants with no score degradation at the time of analysis data cutoff were censored at the date of last assessment showing no degradation.
Time frame: From randomization up to maximum of 18.4 months
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious.
Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)
Percentage of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.
Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)
Percentage of Participants With Adverse Events (AEs) Leading to Death
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.
Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)
Percentage of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.
Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)
| Milestone | Enzalutamide 160 mg | Enzalutamide 160 mg Crossing Over to Abiraterone 1000 mg+ Prednisone 10 mg | Enzalutamide 160 mg+ Abiraterone 1000 mg+ Prednisone 10mg | Placebo + Abiraterone 1000 mg+ Prednisone 10 mg |
|---|---|---|---|---|
| Started | 509 | 0 | 0 | 0 |
| Completed | 264 | 0 | 0 | 0 |
| Not completed | 245 | 0 | 0 | 0 |
| Withdrew: Other | 34 | 0 | 0 | 0 |
| Withdrew: Death | 14 | 0 | 0 | 0 |
| Withdrew: Adverse event | 40 | 0 | 0 | 0 |
| Withdrew: Failure to achieve psa response at week 13 | 43 | 0 | 0 | 0 |
| Withdrew: Disease progression | 92 | 0 | 0 | 0 |
| Withdrew: Protocol non-compliance | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 20 | 0 | 0 | 0 |
| Milestone | Enzalutamide 160 mg | Enzalutamide 160 mg Crossing Over to Abiraterone 1000 mg+ Prednisone 10 mg | Enzalutamide 160 mg+ Abiraterone 1000 mg+ Prednisone 10mg | Placebo + Abiraterone 1000 mg+ Prednisone 10 mg |
|---|---|---|---|---|
| Started | 0 | 13 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 13 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 0 |
| Withdrew: Disease progression | 0 | 11 | 0 | 0 |
| Milestone | Enzalutamide 160 mg | Enzalutamide 160 mg Crossing Over to Abiraterone 1000 mg+ Prednisone 10 mg | Enzalutamide 160 mg+ Abiraterone 1000 mg+ Prednisone 10mg | Placebo + Abiraterone 1000 mg+ Prednisone 10 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 126 | 125 |
| Treated | 0 | 0 | 125 | 124 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 126 | 125 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 3 | 3 |
| Withdrew: Disease progression | 0 | 0 | 104 | 107 |
| Withdrew: Adverse event | 0 | 0 | 14 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 | 8 |
| Withdrew: Protocol non-compliance | 0 | 0 | 0 | 1 |
PFS = time from randomization to first documentation of radiographic progression (RP),unequivocal clinical progression or death due to any cause (death within 112 days of treatment discontinuation without objective evidence of RP),whichever occurred first as per investigator. Unequivocal disease progression was pain requiring chronic administration of analgesics, decline of prostate cancer of Eastern Cooperative Oncology Group (ECOG) performance status score to 3 or higher or initiation of new anticancer therapy/radiation therapy or surgical intervention due to tumor progression. ECOG score range= 0(no severity) to 5(maximum severity).RP for bone disease was evaluated by appearance of 2 or more new bone lesions as per Prostate Cancer Clinical Trials Working Group 2 (PCWG2) or for soft tissue disease according to Response Evaluation Criteria in Solid Tumor version 1.1. Participants with no PFS event at analysis date were censored at last tumor assessment date prior to data cutoff date.
| months | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Progression Free Survival (PFS) | 5.7 (4.6 to 8.1) | 5.6 (4.5 to 7.3) |
Time from date of randomization to the date of first confirmed PSA progression as per Prostate Cancer Clinical Trials Working Group 2 (PCWG2). For participant's whose PSA decreased at Week 13 after randomization, progression was defined as 25 percent (%) PSA increase relative to nadir or absolute increase of \>=2 nanogram/milliliter (ng/mL) above nadir. Progression was confirmed if another assessment measured at least 3 weeks later met the criterion as well. For participant's whose PSA did not decrease at Week 13 after randomization, progression was defined as 25% PSA increase relative to baseline assessed 12 weeks after baseline. Participants who were not known to have had a PFS event at the analysis date were censored at last PSA assessment date prior to data cutoff date.
| months | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Time to Prostate Specific Antigen (PSA) Progression | 2.8 (2.8 to 2.9) | 2.8 (2.8 to 2.8) |
PSA response rate was defined as percentage of participants with \>=30% and \>=50% decrease in PSA from baseline at randomization to the maximal PSA response with a threshold of 30% and 50% respectively. PSA response was confirmed if another assessment measured at least 3 weeks later met the criterion as well.
| percentage of participants | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| >= 50% | 0.8 (0.0 to 4.4) | 2.5 (0.5 to 7.0) |
| >= 30% | 2.4 (0.5 to 6.9) | 2.5 (0.5 to 7.0) |
Objective response rate as assessed by the investigator according to Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST v1.1) was defined as 1) Percentage of participants with confirmed best overall complete response (CR) and partial response (PR); 2) Percentage of participants with CR, PR and stable disease (SD) for target lesions or non-progressive disease for non-target lesions. CR: Disappearance of all non-nodal target and non-target lesions, including target and non-target lymph nodes reduction to \<10 millimeter (mm) in short axis. No new lesions and disappearance of all non-target lesions. PR: \>= 30% decrease in sum of diameters of target lesions, compared to the sum at baseline. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions.
| percentage of participants | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| CR + PR | 0.0 (0.00 to 9.25) | 5.0 (0.61 to 16.92) |
| CR + PR + SD | 68.4 (51.35 to 82.50) | 57.5 (40.89 to 72.96) |
Rate of pain progression was defined as percentage of participants with an increase of \>=30% from baseline in the mean Brief Pain Inventory-Short Form (BPI-SF) pain intensity item scores of 4 items assessing average, worst, least, and intermediate pain severity. BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. BPI-sf includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). BPI-sf score range for each item was from 0=no pain to 10=worst possible pain. Total score was reported as average of individual questions ranges from 0 to 10, where lower scores indicated less pain or less pain interference.
| percentage of participants | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Rate of Pain Progression | 36.2 (24.0 to 49.9) | 27.1 (16.4 to 40.3) |
It was defined as time from randomization to the date of first use of subsequent antineoplastic therapy for prostate cancer. For participants who had not started subsequent antineoplastic therapy as of data analysis cutoff date, the time to first use of subsequent antineoplastic therapy was censored at the date of last assessment.
| months | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Time to First Use of New Antineoplastic Therapy for Prostate Cancer | 10.3 (8.7 to 12.1) | 8.6 (7.4 to 11.7) |
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 where higher scores represent better quality of life.
| units on a scale | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Baseline | 116.4 ± 20.10 | 119.0 ± 19.08 |
| Change at Week 9 | -3.3 ± 14.90 | -2.2 ± 13.90 |
| Change at Week 13 | -4.4 ± 14.44 | -0.5 ± 13.02 |
| Change at Week 17 | -3.7 ± 12.40 | -2.3 ± 13.90 |
| Change at Week 21 | -2.5 ± 12.33 | -2.7 ± 13.57 |
| Change at Week 25 | -3.1 ± 13.47 | -2.1 ± 10.87 |
| Change at Week 29 | -6.8 ± 13.98 | 0.3 ± 12.10 |
| Change at Week 33 | -5.9 ± 15.35 | -0.2 ± 12.90 |
| Change at Week 37 | -6.1 ± 14.25 | 0.9 ± 12.57 |
| Change at Week 41 | -5.7 ± 12.17 | 1.3 ± 14.13 |
| Change at Week 45 | -6.0 ± 9.56 | -2.6 ± 16.27 |
| Change at Week 49 | -4.2 ± 11.36 | 1.8 ± 10.74 |
| Change at Week 53 | -4.8 ± 10.17 | 1.8 ± 14.68 |
| Change at Week 57 (n =17, 13) | -4.3 ± 9.73 | 0.1 ± 7.45 |
| Change at Week 61 | -5.5 ± 10.63 | 0.6 ± 12.94 |
| Change at Week 65 | -7.0 ± 7.86 | 1.9 ± 9.50 |
| Change at Week 69 | -3.5 ± 11.37 | 4.4 ± 13.29 |
| Change at Week 73 | -0.7 ± 7.26 | -35.0 ± NA |
| Change at Week 77 | -4.0 ± 9.81 | 6.5 ± 30.41 |
| Change at Week 81 | 10.8 ± 9.24 | — |
| Change at Week 85 | -5.5 ± 3.54 | — |
| Change at Week 89 | -2.0 ± NA | — |
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for social/family well-being domain is from 0 (worst response) to 32 (best response), where higher score indicate better quality of life.
| units on a scale | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Baseline | 22.1 ± 5.80 | 22.4 ± 4.84 |
| Change at Week 9 | -0.5 ± 4.33 | -0.8 ± 4.13 |
| Change at Week 13 | -0.4 ± 3.46 | -0.4 ± 3.86 |
| Change at Week 17 | -0.1 ± 3.68 | -0.6 ± 4.64 |
| Change at Week 21 | -0.5 ± 3.24 | -1.2 ± 5.75 |
| Change at Week 25 | 0.1 ± 2.79 | -1.0 ± 5.25 |
| Change at Week 29 | -0.1 ± 3.20 | -0.2 ± 5.18 |
| Change at Week 33 | -0.2 ± 3.21 | 0.0 ± 4.95 |
| Change at Week 37 | -0.8 ± 3.04 | 0.8 ± 2.79 |
| Change at Week 41 | -1.4 ± 3.75 | -0.1 ± 3.51 |
| Change at Week 45 | -0.9 ± 3.36 | -0.8 ± 3.75 |
| Change at Week 49 | -0.6 ± 2.88 | 0.0 ± 2.65 |
| Change at Week 53 | -1.0 ± 3.15 | 0.4 ± 2.56 |
| Change at Week 57 | -2.0 ± 3.06 | 0.2 ± 1.29 |
| Change at Week 61 | -1.5 ± 2.77 | -0.2 ± 1.80 |
| Change at Week 65 | -1.5 ± 2.54 | -0.5 ± 0.96 |
| Change at Week 69 | -1.4 ± 2.03 | -0.5 ± 0.96 |
| Change at Week 73 | -0.6 ± 3.22 | -1.0 ± NA |
| Change at Week 77 | -0.9 ± 3.41 | -0.5 ± 0.71 |
| Change at Week 81 | 6.2 ± 5.42 | — |
| Change at Week 85 | -1.0 ± 1.41 | — |
| Change at Week 89 | 0.0 ± NA | — |
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for emotional well-being domain is from 0 (worst response) to 24 (best response), where higher score indicate better quality of life.
| units on a scale | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Baseline | 18.1 ± 3.80 | 18.5 ± 4.06 |
| Change at Week 9 | -0.1 ± 2.81 | 0.1 ± 3.40 |
| Change at Week 13 | -0.1 ± 3.55 | 0.2 ± 3.09 |
| Change at Week 17 | -0.2 ± 3.44 | 0.4 ± 2.88 |
| Change at Week 21 | 0.3 ± 3.48 | 0.1 ± 3.36 |
| Change at Week 25 | 0.3 ± 2.58 | 0.3 ± 3.33 |
| Change at Week 29 | -0.5 ± 3.56 | 0.3 ± 3.27 |
| Change at Week 33 | 0.1 ± 3.33 | 0.9 ± 2.99 |
| Change at Week 37 | -0.7 ± 4.04 | 0.9 ± 2.49 |
| Change at Week 41 | 0.1 ± 2.99 | 1.4 ± 2.60 |
| Change at Week 45 | -0.5 ± 3.23 | 1.2 ± 2.76 |
| Change at Week 49 | 0.0 ± 3.00 | 1.3 ± 2.75 |
| Change at Week 53 | 0.1 ± 2.72 | 1.2 ± 3.23 |
| Change at Week 57 | -0.4 ± 2.32 | 1.6 ± 2.53 |
| Change at Week 61 | -0.3 ± 3.14 | 1.1 ± 3.62 |
| Change at Week 65 | -0.9 ± 3.57 | 2.9 ± 2.54 |
| Change at Week 69 | -0.5 ± 2.93 | 1.5 ± 2.93 |
| Change at Week 73 | 1.0 ± 2.83 | -5.0 ± 5.66 |
| Change at Week 77 | 0.1 ± 2.67 | 2.0 ± 2.83 |
| Change at Week 81 | 1.5 ± 3.54 | — |
| Change at Week 85 | -1.5 ± 0.71 | — |
| Change at Week 89 | -3.0 ± NA | — |
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for functional well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.
| units on a scale | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Baseline | 20.2 ± 5.54 | 20.3 ± 5.84 |
| Change at Week 9 | -1.0 ± 4.23 | -0.7 ± 4.62 |
| Change at Week 13 | -1.2 ± 4.07 | -0.4 ± 4.54 |
| Change at Week 17 | -1.3 ± 4.00 | -0.5 ± 4.11 |
| Change at Week 21 | -1.2 ± 5.03 | -0.7 ± 4.03 |
| Change at Week 25 | -1.0 ± 3.41 | -0.3 ± 4.41 |
| Change at Week 29 | -2.4 ± 4.67 | -0.2 ± 4.38 |
| Change at Week 33 | -2.0 ± 5.14 | -0.7 ± 4.49 |
| Change at Week 37 | -1.5 ± 5.22 | 0.2 ± 5.72 |
| Change at Week 41 | -2.1 ± 4.44 | 0.8 ± 5.74 |
| Change at Week 45 | -2.0 ± 3.37 | -0.3 ± 6.28 |
| Change at Week 49 | -2.1 ± 4.55 | 1.5 ± 5.02 |
| Change at Week 53 | -1.6 ± 4.67 | 1.3 ± 4.92 |
| Change at Week 57 | -1.4 ± 4.06 | 2.0 ± 4.37 |
| Change at Week 61 | -0.8 ± 3.34 | 2.9 ± 5.56 |
| Change at Week 65 | -1.2 ± 2.21 | 1.7 ± 2.75 |
| Change at Week 69 | 0.2 ± 1.48 | 2.3 ± 4.23 |
| Change at Week 73 | -0.6 ± 3.02 | 4.0 ± 12.73 |
| Change at Week 77 | -1.6 ± 3.91 | 2.5 ± 9.19 |
| Change at Week 81 | -1.5 ± 7.78 | — |
| Change at Week 85 | -1.5 ± 2.12 | — |
| Change at Week 89 | 1.0 ± NA | — |
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for prostate cancer domain is from 0 (worst response) to 48 (best response), where higher score indicated better quality of life with fewer symptoms.
| units on a scale | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Baseline | 33.2 ± 6.85 | 34.2 ± 6.45 |
| Change at Week 9 | -0.7 ± 5.97 | -0.9 ± 5.18 |
| Change at Week 13 | -1.9 ± 5.91 | -0.1 ± 5.36 |
| Change at Week 17 | -1.0 ± 5.36 | -1.4 ± 5.10 |
| Change at Week 21 | -0.4 ± 5.13 | -0.6 ± 4.83 |
| Change at Week 25 | -0.8 ± 6.93 | -0.8 ± 4.42 |
| Change at Week 29 | -1.3 ± 5.75 | -0.3 ± 4.77 |
| Change at Week 33 | -1.4 ± 5.16 | -0.6 ± 4.88 |
| Change at Week 37 | -1.5 ± 4.88 | -0.8 ± 4.32 |
| Change at Week 41 | -1.0 ± 5.13 | -0.7 ± 5.34 |
| Change at Week 45 | -0.8 ± 4.88 | -1.7 ± 7.02 |
| Change at Week 49 | -0.8 ± 4.26 | -0.9 ± 4.63 |
| Change at Week 53 | -1.1 ± 3.65 | -1.8 ± 5.78 |
| Change at Week 57 | -0.5 ± 3.67 | -3.3 ± 4.48 |
| Change at Week 61 | -2.1 ± 4.29 | -3.1 ± 5.68 |
| Change at Week 65 | -2.0 ± 4.05 | -2.6 ± 6.32 |
| Change at Week 69 | -1.5 ± 3.30 | 1.1 ± 5.79 |
| Change at Week 73 | -0.2 ± 3.17 | -6.4 ± 9.32 |
| Change at Week 77 | -1.0 ± 3.71 | -1.5 ± 13.44 |
| Change at Week 81 | 3.1 ± 1.22 | — |
| Change at Week 85 | -0.5 ± 0.71 | — |
| Change at Week 89 | 0.0 ± NA | — |
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for physical well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.
| units on a scale | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Baseline | 22.9 ± 4.50 | 23.6 ± 4.42 |
| Change at Week 9 | -0.8 ± 4.04 | 0.1 ± 3.20 |
| Change at Week 13 | -1.0 ± 4.11 | 0.0 ± 2.63 |
| Change at Week 17 | -1.1 ± 3.26 | -0.3 ± 2.97 |
| Change at Week 21 | -0.8 ± 3.11 | -0.8 ± 4.48 |
| Change at Week 25 | -1.7 ± 4.23 | -0.4 ± 2.90 |
| Change at Week 29 | -2.5 ± 4.89 | 0.3 ± 2.67 |
| Change at Week 33 | -2.5 ± 5.37 | 0.1 ± 3.18 |
| Change at Week 37 | -1.8 ± 4.50 | 0.4 ± 3.13 |
| Change at Week 41 | -1.5 ± 3.94 | 0.4 ± 2.80 |
| Change at Week 45 | -2.0 ± 3.72 | -0.4 ± 3.59 |
| Change at Week 49 | -0.9 ± 3.78 | 0.6 ± 2.12 |
| Change at Week 53 | -0.2 ± 3.78 | 0.7 ± 2.85 |
| Change at Week 57 | -0.4 ± 3.25 | 0.4 ± 2.37 |
| Change at Week 61 | -0.8 ± 3.11 | 0.4 ± 2.32 |
| Change at Week 65 | -1.9 ± 4.25 | 0.4 ± 1.99 |
| Change at Week 69 | -0.3 ± 4.08 | -0.5 ± 2.67 |
| Change at Week 73 | -0.3 ± 2.05 | -3.0 ± 5.66 |
| Change at Week 77 | -0.7 ± 2.81 | 4.0 ± 4.24 |
| Change at Week 81 | 1.5 ± 2.12 | — |
| Change at Week 85 | -1.0 ± 0.00 | — |
| Change at Week 89 | 0.0 ± NA | — |
Time to degradation of FACT-P was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the global FACT-P score for each participant. The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, and functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 with higher scores representing better quality of life. Participants with no score degradation at the time of analysis data cutoff were censored at the date of last assessment showing no degradation.
| months | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|
| Time to Degradation of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score | 4.6 (3.7 to 6.5) | 6.4 (5.5 to 13.9) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious.
| percentage of participants | Enzalutamide 160 mg | Enzalutamide Crossing Over to Abiraterone + Prednisone | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|---|---|
| AEs | 93.5 | 100 | 91.2 | 92.7 |
| SAEs | 32.0 | 30.8 | 37.6 | 29.8 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.
| percentage of participants | Enzalutamide 160 mg | Enzalutamide Crossing Over to Abiraterone + Prednisone | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|---|---|
| Drug Discontinuation with Enzalutamide or Placebo | 11.8 | — | 23.2 | 11.3 |
| Drug Discontinuation with Abiraterone | — | 7.7 | 23.2 | 12.9 |
| Drug Discontinuation with Prednisone | — | 7.7 | 16.0 | 12.1 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.
| percentage of participants | Enzalutamide 160 mg | Enzalutamide Crossing Over to Abiraterone + Prednisone | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Leading to Death | 5.9 | 0 | 3.2 | 2.4 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.
| percentage of participants | Enzalutamide 160 mg | Enzalutamide Crossing Over to Abiraterone + Prednisone | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo+Abiraterone 1000mg+ Prednisone 10mg |
|---|---|---|---|---|
| TEAEs related to Enzalutamide or Placebo | 66.6 | — | 46.4 | 36.3 |
| TEAEs related to Abiraterone | — | 38.5 | 54.4 | 45.2 |
| TEAEs related to Prednisone | — | 7.7 | 36.0 | 32.3 |
| SAEs related to Enzalutamide or Placebo | 4.1 | — | 7.2 | 4.8 |
| SAEs related to Abiraterone | — | 0 | 7.2 | 4.0 |
| SAEs related to Prednisone | — | 0 | 2.4 | 4.8 |
Collected over Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum duration of exposure: 99.4 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide 160 mg | 32/509 (6.3%) | 163/509 (32%) | 474/509 (93.1%) |
| Enzalutamide Crossing Over to Abiraterone + Prednisone | 1/13 (7.7%) | 4/13 (30.8%) | 13/13 (100%) |
| Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | 14/126 (11.1%) | 47/125 (37.6%) | 113/125 (90.4%) |
| Placebo + Abiraterone 1000 mg + Prednisone 10mg | 10/125 (8%) | 37/124 (29.8%) | 113/124 (91.1%) |
| Event | Enzalutamide 160 mg | Enzalutamide Crossing Over to Abiraterone + Prednisone | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo + Abiraterone 1000 mg + Prednisone 10mg |
|---|---|---|---|---|
| Myocardial ischaemiaCardiac disorders | 1/509 | 1/13 | 1/125 | 0/124 |
| GastroenteritisInfections and infestations | 1/509 | 1/13 | 0/125 | 0/124 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/509 | 1/13 | 1/125 | 0/124 |
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/509 | 1/13 | 0/125 | 0/124 |
| Spinal cord compressionNervous system disorders | 5/509 | 0/13 | 5/125 | 2/124 |
| PneumoniaInfections and infestations | 7/509 | 0/13 | 1/125 | 3/124 |
| Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/509 | 0/13 | 3/125 | 2/124 |
| HaematuriaRenal and urinary disorders | 11/509 | 0/13 | 3/125 | 1/124 |
| Myocardial infarctionCardiac disorders | 2/509 | 0/13 | 0/125 | 2/124 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/509 | 0/13 | 0/125 | 2/124 |
| Event | Enzalutamide 160 mg | Enzalutamide Crossing Over to Abiraterone + Prednisone | Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg | Placebo + Abiraterone 1000 mg + Prednisone 10mg |
|---|---|---|---|---|
| FatigueGeneral disorders | 206/509 | 0/13 | 20/125 | 19/124 |
| Back painMusculoskeletal and connective tissue disorders | 112/509 | 1/13 | 26/125 | 28/124 |
| NauseaGastrointestinal disorders | 100/509 | 0/13 | 23/125 | 12/124 |
| HypertensionVascular disorders | 52/509 | 0/13 | 24/125 | 11/124 |
| Hot flushVascular disorders | 90/509 | 1/13 | 8/125 | 3/124 |
| ConstipationGastrointestinal disorders | 84/509 | 0/13 | 22/125 | 14/124 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 78/509 | 2/13 | 22/125 | 16/124 |
| Decreased appetiteMetabolism and nutrition disorders | 83/509 | 2/13 | 14/125 | 11/124 |
| FallInjury, poisoning and procedural complications | 51/509 | 2/13 | 14/125 | 10/124 |
| Rib fractureInjury, poisoning and procedural complications | 5/509 | 2/13 | 1/125 | 1/124 |
ITT (Intent to treat) population included all participants randomly assigned to study treatment.
| Age, Continuous(years) | Enzalutamide 160 mg |
|---|---|
| Mean | 72.3 ± 8.31 |
| Sex: Female, Male(Participants) | Enzalutamide 160 mg |
|---|---|
| Female | 0 |
| Male | 509 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2013 to primary completion in Nov 2016, 36 months.
Results were first posted in Nov 2017, 1 year after primary completion.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 36 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide